TG Therapeutics Inc

TGTX

Equity

ISIN null / Valor 18511671

NASDAQ (2026-03-27)

USD 31.75-0.72%

TG Therapeutics Inc
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

TG Therapeutics Inc is a biopharmaceutical company listed on the NASDAQ under the ticker symbol TGTX. The company focuses on developing innovative therapies for various diseases, with a particular emphasis on autoimmune and oncology conditions. One of its key products is BRIUMVI ® (ublituximab-xiiy), which is currently undergoing Phase 3 trials for the treatment of relapsing forms of multiple sclerosis (RMS). Through its research and development efforts, TG Therapeutics Inc aims to bring novel treatment options to patients in need.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-21.0%1Y

112%3Y

-31.1%5Y

Performance

47.3%1Y

76.6%3Y

89.6%5Y

Volatility

5070 M

Market cap (USD)

1,523,797

Daily traded volume (Shares)

32.3 / 31.23

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

5.00

1 votes

Performance:

5.00

Innovation:

5.00

Society:

5.00

Nature:

5.00

Luba Schoenig

Switzerland, 14 Jan 2025

On January 14, 2025, TG Therapeutics announced preliminary net revenue results for the fourth quarter and full year of 2024, along with anticipated development milestones for 2025. The company revised its guidance upward, driven by stronger-than-expected sales of its multiple sclerosis drug, Briumvi

EQUITIES OF THE SAME SECTOR

Softing AG